Cheetah Range Drops 90 Percent

Estimating only 7,100 individuals remaining, researchers urge a reclassification of the species from vulnerable to endangered.

Dec 27, 2016
Kerry Grens

WIKIMEDIA, SIDDHARTH MAHESHWARIThe cheetah (Acinonyx jubatus) now roams nine percent of its former habitat, and just 7,100 of the cats remain globally, researchers reported this week (December 26) in PNAS. The authors of the study note that roughly 75 percent of the animals’ range exists beyond protected areas, and support reclassifying the cheetah from “vulnerable” to “endangered” on the International Union for the Conservation of Nature Red List.

“Given the secretive nature of this elusive cat, it has been difficult to gather hard information on the species, leading to its plight being overlooked,” said lead author Sarah Durant of the Zoological Society of London, in a press release. “The large space requirements for cheetah, coupled with the complex range of threats faced by the species in the wild, mean that it is likely to be much more vulnerable to extinction than was previously thought."

In unprotected areas, cheetah numbers are threatened by “human–wildlife conflict, prey loss caused by overhunting and bushmeat harvesting, habitat loss and fragmentation, and illegal trade,” Durant and colleagues wrote in their report.

Cheetahs used to prowl across large swaths of Africa and Asia—about 33 million km2— but Durant and her colleagues found they now occupy barely 3.1 million km2. Given that much of this land is in unprotected areas, Durant’s group proposes a conservation strategy that focuses on population growth beyond protected regions. “New policy, management, and financial tools are needed that promote coexistence between people and wildlife outside and adjacent to [protected areas],” Durant and her team concluded.                                                            

“It’s a timely paper,” Yeneneh Teka, an environmental specialist at the US Department of State who was not involved in the study, told The Atlantic. “It should help to alert policy makers that the cheetah population is declining and measures have to be in place to save those outside protected areas.”

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb


Sponsored Product Updates

Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to includeex vivoT lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery,enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.
pIC50: The Advantages of Thinking Logarithmically
pIC50: The Advantages of Thinking Logarithmically
Watch this webinar from Collaborative Drug Discovery to learn about how using pIC50 helps you get a better sense of the relative potencies, calculate the correct mean of multiple values, and select better sampling doses.
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.